• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用纤溶酶原预防透明膜病。一项合作研究。

Prevention of hyaline membrane disease with plasminogen. A cooperative study.

作者信息

Ambrus C M, Choi T S, Cunnanan E, Eisenberg B, Staub H P, Weintraub D H, Courey N G, Patterson R J, Jockin H, Pickren J W, Bross I D, Jung O S, Ambrus J L

出版信息

JAMA. 1977 Apr 25;237(17):1837-41.

PMID:321823
Abstract

In a double-blind, randomized study, 500 premature infants were treated with plasminogen or placebo intravenously within 60 minutes of birth. There was a substantial decrease in severe clinical respiratory distress, death caused by hyaline membrane disease, and total mortality in the plasminogen-treated infants as compared to the controls.

摘要

在一项双盲随机研究中,500名早产婴儿在出生后60分钟内静脉注射纤溶酶原或安慰剂。与对照组相比,接受纤溶酶原治疗的婴儿严重临床呼吸窘迫、透明膜病导致的死亡及总死亡率均大幅降低。

相似文献

1
Prevention of hyaline membrane disease with plasminogen. A cooperative study.用纤溶酶原预防透明膜病。一项合作研究。
JAMA. 1977 Apr 25;237(17):1837-41.
2
Prevention of hyaline membrane disease with plasminogen. Preliminary report of a cooperative study.用纤溶酶原预防透明膜病。一项合作研究的初步报告。
Res Commun Chem Pathol Pharmacol. 1976 Sep;15(1):195-8.
3
Plasminogen in the prevention of hyaline membrane disease.纤溶酶原在预防透明膜病中的作用。
Am J Dis Child. 1974 Feb;127(2):189-94. doi: 10.1001/archpedi.1974.02110210039005.
4
Studies on the prevention of respiratory distress syndrome of infants due to hyaline membrane disease with plasminogen.关于用纤溶酶原预防婴儿因透明膜病所致呼吸窘迫综合征的研究。
Semin Thromb Hemost. 1975 Jul;2(1):42-51. doi: 10.1055/s-0028-1086114.
5
Plasminogen in the prevention of hyaline membrane disease.纤溶酶原在预防透明膜病中的作用。
Res Commun Chem Pathol Pharmacol. 1973 Jul;6(1):341-4.
6
Changes in the fibrinolysin system in infantile and adult respiratory distress syndrome (ARDS), caused by trauma and/or septic shock in patients and in experimental animals.由患者和实验动物的创伤和/或脓毒性休克引起的婴儿和成人呼吸窘迫综合征(ARDS)中纤维蛋白溶解系统的变化。
J Med. 1990;21(1-2):67-84.
7
The fibrinolytic enzyme defect of hyaline membrane disease.透明膜病的纤溶酶缺陷
Calif Med. 1961 Nov;95(5):278-82.
8
Pathways of fibrin turnover in lavage of premature baboons with hyperoxic lung injury.高氧肺损伤早产狒狒灌洗中纤维蛋白周转途径
Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):767-75. doi: 10.1164/ajrccm.149.3.8118648.
9
Double-blind clinical trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants.小牛肺表面活性物质提取物预防极早产儿透明膜病的双盲临床试验。
Pediatrics. 1985 Oct;76(4):585-92.
10
A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants.一项关于产前使用糖皮质激素预防早产儿呼吸窘迫综合征的对照试验。
Pediatrics. 1972 Oct;50(4):515-25.

引用本文的文献

1
Emerging patterns of hypercoagulability associated with critical COVID-19: A review.与重症新型冠状病毒肺炎相关的高凝状态新趋势:综述
Trends Anaesth Crit Care. 2020 Oct;34:4-13. doi: 10.1016/j.tacc.2020.07.004. Epub 2020 Jul 9.
2
Role of Tissue-Type Plasminogen Activator in Remodeling of the Ductus Arteriosus.组织型纤溶酶原激活剂在动脉导管重塑中的作用。
Circ Rep. 2020 Mar 28;2(4):211-217. doi: 10.1253/circrep.CR-20-0015.
3
Plasminogen improves lung lesions and hypoxemia in patients with COVID-19.纤溶酶原可改善 COVID-19 患者的肺部病变和低氧血症。
QJM. 2020 Aug 1;113(8):539-545. doi: 10.1093/qjmed/hcaa121.
4
Tissue-type plasminogen activator contributes to remodeling of the rat ductus arteriosus.组织型纤溶酶原激活剂有助于大鼠动脉导管的重塑。
PLoS One. 2018 Jan 5;13(1):e0190871. doi: 10.1371/journal.pone.0190871. eCollection 2018.
5
The ins and outs of respiratory distress syndrome in babies and adults.婴儿和成人呼吸窘迫综合征的来龙去脉。
J R Coll Physicians Lond. 1994 Jan-Feb;28(1):24-33.